+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Duchenne Muscular Dystrophy Drugs - Global Market Trajectory & Analytics

  • ID: 4804175
  • Report
  • April 2021
  • Region: Global
  • 133 Pages
  • Global Industry Analysts, Inc
Global Duchenne Muscular Dystrophy Drugs Market to Reach $7 Billion by 2027

Amid the COVID-19 crisis, the global market for Duchenne Muscular Dystrophy Drugs estimated at US$706.5 Million in the year 2020, is projected to reach a revised size of US$7 Billion by 2027, growing at a CAGR of 38.8% over the analysis period 2020-2027. Mutation Suppression, one of the segments analyzed in the report, is projected to record a 37.2% CAGR and reach US$2.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Exon Skipping segment is readjusted to a revised 40% CAGR for the next 7-year period.



The U.S. Market is Estimated at $213.2 Million, While China is Forecast to Grow at 37.6% CAGR

The Duchenne Muscular Dystrophy Drugs market in the U.S. is estimated at US$213.2 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2027 trailing a CAGR of 37.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 34.7% and 33.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 27.5% CAGR.

Other Segments Segment to Record 31% CAGR

In the global Other Segments segment, USA, Canada, Japan, China and Europe will drive the 31% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$15.3 Million in the year 2020 will reach a projected size of US$101.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$855.7 Million by the year 2027.

Select Competitors (Total 46 Featured):
  • Acceleron Pharma, Inc.
  • Akashi Therapeutics, Inc.
  • BioMarin Pharmaceutical, Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Janssen Pharmaceuticals, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Nippon Shokubai Co., Ltd.
  • Nobelpharma Co., Ltd.
  • Pfizer, Inc.
  • PTC Therapeutics, Inc.
  • Sarepta Therapeutics Inc.
  • Taiho Pharmaceutical Co., Ltd.
Frequently Asked Questions about the Global Market for Duchenne Muscular Dystrophy Drugs

What is the estimated value of the Global Market for Duchenne Muscular Dystrophy Drugs?

The Global Market for Duchenne Muscular Dystrophy Drugs was estimated to be valued at $706.5 Million in 2020.

What is the growth rate of the Global Market for Duchenne Muscular Dystrophy Drugs?

The growth rate of the Global Market for Duchenne Muscular Dystrophy Drugs is 38.8%, with an estimated value of $7000.0 Million by 2027.

What is the forecasted size of the Global Market for Duchenne Muscular Dystrophy Drugs?

The Global Market for Duchenne Muscular Dystrophy Drugs is estimated to be worth $7000.0 Million by 2027.
Note: Product cover images may vary from those shown

I. METHODOLOGY
II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • World Market Trajectories
  • Duchenne Muscular Dystrophy (DMD) Drugs Market To Exhibit Strong Growth
  • Impact of Covid-19 and a Looming Global Recession
  • Global Market Dynamics
  • Treatment Overview and Recent Developments
  • Steroids used for the Treatment of DMD
  • Translarna Exhibits Positive Result in Children with DMD
  • Clinical Trials Depict Emflaza Preserves Motor Function Better than Corticosteroids
  • Trial Shows Golodirsen Increases Dystrophin Production in DMD Patients
  • Casimersen and Golodirsen Exhibits Positive Results in Sarepta’s ESSENCE study
  • EXONDYS 51® Drug Details
  • FDA Approves Corticosteroid Emflaza for Treating DMD Patients
  • Pipeline Analysis
  • Drug Price Details: Exondys51
  • Sarepta’s DMD Gene Therapy Trial Update
  • Table 1: World Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Duchenne Muscular Dystrophy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Duchenne Muscular Dystrophy Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for Mutation Suppression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Mutation Suppression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for Mutation Suppression by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Exon Skipping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Exon Skipping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Exon Skipping by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS
  • Table 13: USA Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 14: USA Historic Review for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 15: USA 15-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Mutation Suppression, Exon Skipping and Other Segments for the Years 2012, 2020 & 2027
  • Table 16: Canada Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 17: Canada Historic Review for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 18: Canada 15-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Mutation Suppression, Exon Skipping and Other Segments for the Years 2012, 2020 & 2027
  • Table 19: Japan Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 20: Japan Historic Review for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 21: Japan 15-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Mutation Suppression, Exon Skipping and Other Segments for the Years 2012, 2020 & 2027
  • Table 22: China Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 23: China Historic Review for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 24: China 15-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Mutation Suppression, Exon Skipping and Other Segments for the Years 2012, 2020 & 2027
  • Irish Boys with nonsense mutation Duchenne muscular dystrophy (nmDMD) Gains Access to Key, Life-Supporting Drug
  • CHMP Rejects Exondys 51 in Europe
  • Table 25: Europe Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 26: Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 27: Europe 15-Year Perspective for Duchenne Muscular Dystrophy Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 28: Europe Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 29: Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 30: Europe 15-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Mutation Suppression, Exon Skipping and Other Segments for the Years 2012, 2020 & 2027
  • Table 31: France Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 32: France Historic Review for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 33: France 15-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Mutation Suppression, Exon Skipping and Other Segments for the Years 2012, 2020 & 2027
  • Table 34: Germany Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 35: Germany Historic Review for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 36: Germany 15-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Mutation Suppression, Exon Skipping and Other Segments for the Years 2012, 2020 & 2027
  • Table 37: Italy Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 38: Italy Historic Review for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 39: Italy 15-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Mutation Suppression, Exon Skipping and Other Segments for the Years 2012, 2020 & 2027
  • Table 40: UK Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 41: UK Historic Review for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 42: UK 15-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Mutation Suppression, Exon Skipping and Other Segments for the Years 2012, 2020 & 2027
  • Table 43: Rest of Europe Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 44: Rest of Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 45: Rest of Europe 15-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Mutation Suppression, Exon Skipping and Other Segments for the Years 2012, 2020 & 2027
  • Table 46: Asia-Pacific Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 47: Asia-Pacific Historic Review for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 48: Asia-Pacific 15-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Mutation Suppression, Exon Skipping and Other Segments for the Years 2012, 2020 & 2027
  • Table 49: Rest of World Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 50: Rest of World Historic Review for Duchenne Muscular Dystrophy Drugs by Segment - Mutation Suppression, Exon Skipping and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 51: Rest of World 15-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Mutation Suppression, Exon Skipping and Other Segments for the Years 2012, 2020 & 2027

IV. COMPETITION
  • Total Companies Profiled: 46
Note: Product cover images may vary from those shown